Raphael Pharmaceutical (RAPH) Accounts Payables (2020 - 2025)

Raphael Pharmaceutical (RAPH) has 6 years of Accounts Payables data on file, last reported at $163000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 30.4% year-over-year to $163000.0; the trailing twelve-month figure through Dec 2025 stood at $163000.0 (up 30.4% YoY), and the FY2025 full-year result was $163000.0, up 30.4% from the prior year.
• Accounts Payables grew to $163000.0 in Q4 2025, from $125000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $272000.0 in Q4 2021 to a low of $12000.0 in Q3 2021.
• A 5-year average of $118833.3 and a median of $98500.0 in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 2922.22% in 2021 and sank 73.53% in 2022, its largest moves.
• Tracing RAPH's Accounts Payables over 5 years: stood at $272000.0 in 2021, then slumped by 73.53% to $72000.0 in 2022, then slipped by 4.17% to $69000.0 in 2023, then soared by 81.16% to $125000.0 in 2024, then surged by 30.4% to $163000.0 in 2025.
• Business Quant data shows RAPH's Accounts Payables at $163000.0 in Q4 2025, $125000.0 in Q4 2024, and $69000.0 in Q4 2023.